Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
3.530
+0.330 (10.31%)
At close: Apr 25, 2025, 4:00 PM
3.510
-0.020 (-0.57%)
After-hours: Apr 25, 2025, 4:19 PM EDT
Mainz Biomed Employees
As of December 31, 2024, Mainz Biomed had 26 total employees, including 19 full-time and 7 part-time employees. The number of employees decreased by 45 or -63.38% compared to the previous year.
Employees
26
Change (1Y)
-45
Growth (1Y)
-63.38%
Revenue / Employee
$34,384
Profits / Employee
-$832,718
Market Cap
10.73M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26 | -45 | -63.38% |
Dec 31, 2023 | 71 | 7 | 10.94% |
Dec 31, 2022 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MYNZ News
- 4 weeks ago - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 6 weeks ago - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewsWire
- 2 months ago - Mainz Biomed Expands into Switzerland with labor team w - GlobeNewsWire
- 2 months ago - Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month - GlobeNewsWire
- 3 months ago - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewsWire
- 3 months ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - GlobeNewsWire
- 4 months ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire